Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Tradewinds LLC.

Tradewinds LLC. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% during the 3rd quarter, Holdings Channel reports. The fund owned 5,186 shares of the biopharmaceutical company’s stock after selling 279 shares during the quarter. Tradewinds LLC.’s holdings in Gilead Sciences were worth $435,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc grew its stake in shares of Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the period. Dimensional Fund Advisors LP grew its position in Gilead Sciences by 2.6% during the second quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company’s stock valued at $714,421,000 after buying an additional 268,208 shares during the period. Pacer Advisors Inc. grew its position in Gilead Sciences by 24.7% during the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock valued at $541,310,000 after buying an additional 1,564,792 shares during the period. Van ECK Associates Corp raised its position in shares of Gilead Sciences by 0.4% in the third quarter. Van ECK Associates Corp now owns 6,342,831 shares of the biopharmaceutical company’s stock worth $553,285,000 after acquiring an additional 22,847 shares during the period. Finally, Federated Hermes Inc. boosted its stake in shares of Gilead Sciences by 19.6% during the 2nd quarter. Federated Hermes Inc. now owns 6,321,167 shares of the biopharmaceutical company’s stock worth $433,695,000 after acquiring an additional 1,036,932 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. Wells Fargo & Company lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Citigroup started coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Finally, Robert W. Baird increased their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Twelve analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 27.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,947 shares of company stock worth $4,968,674. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $88.63 on Thursday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The stock’s fifty day moving average is $87.15 and its two-hundred day moving average is $76.52. The company has a market capitalization of $110.46 billion, a P/E ratio of 984.78, a P/E/G ratio of 2.72 and a beta of 0.17. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 4.38 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.48%. Gilead Sciences’s payout ratio is currently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.